Tunable TriPcides suppress virulence factor secretion during <i>Staphylococcus aureus</i> infection and kill dormant cells.

Abstract

Antimicrobial resistance (AMR) in common bacterial pathogens, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), is an increasingly dire public health threat, with MRSA accounting for up to 90% of <i>S. aureus</i> infections. To expand the treatment arsenal against MRSA infections, we developed a class of tunable three-dimensional tricyclic 2-pyridones, termed TriPcides, that can kill MRSA resistant to last-resort antibiotics and eliminate MRSA persister cells. No preexisting resistance was detected across hundreds of clinical isolates, and continuous exposure of MRSA to TriPcides did not elicit detectable resistance. Treatment with TriPcides causes a rapid decrease in membrane integrity and increased levels of reactive oxygen species. Last, TriPcides effectively reduce secretion of important virulence factors and result in reduced ulcer size and healing time in <i>S. aureus</i> murine skin and soft tissue infections but do not reduce bacterial burden.